


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


Kaitin KI, editor. 75% of U.S. health plans reimburse off-label uses of prescription drugs. *Tufts Center for the Study of Drug Development Impact Report* 2009 Mar/Apr;11(2)**


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2901 Kaitin, KI editor. Current investigator landscape poses a growing challenge for sponsors. Tufts Center for the Study of Drug Development Impact Report 2009 Jan/Feb;11(1)**


RS 2831 Milne C-P Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clinical Therapeutics 2008 Nov;30(11):2133-45


RS 2827 Kaitin KI, editor. Fast track designations more than doubled during the last five years. Tufts Center for the Study of Drug Development Impact Report 2008 Sep/Oct;10(5)**

RS 2826 Getz KA. Restoring public confidence in clinical research. ACRP Monitor 2008 Sep;22(5):59-62

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu
RS 2825  Getz KA. Public confidence and trust today. *ACRP Monitor* 2008 Sep;22(5):17-21


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu
RS 2815  Getz K. Beyond outsourcing (interview by Jenefer Trevena).  *Scrip Supplement Contract Research Update* 2008 Apr;4:5-6


RS 2811  Getz K.  The heavy burden of protocol design.  *Applied Clinical Trials* 2008 May;17(1)  

RS 2810  Getz K.  Tracking racial disparities in research.  *Applied Clinical Trials* 2008 Jan;17(1)  

RS 2809  Getz KA.  In search of efficiency between trial phases.  *Applied Clinical Trials* 2008 Mar;17(3)  
http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Clinical+Trial+Insights/In-Search-of-Efficiency-Between-Trial-Phases/ArticleStandard/Article/detail/500433?contextCategoryId=37194


RS 2807  Kaitin KI, editor.  Number of mAbs entering clinical study nearly tripled in last decade.  *Tufts Center for the Study of Drug Development Impact Report* 2008 Mar/APR;10(2)**

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2802  Kaitin KI.  Obstacles and opportunities in new drug development.  *Clinical Pharmacology & Therapeutics* 2008 Feb;83(2):210-2  
[http://www.nature.com/clpt/journal/v83/n2/pdf/6100462a.pdf](http://www.nature.com/clpt/journal/v83/n2/pdf/6100462a.pdf)


RS 2729  Getz KA.  In search of informed consent improvement.  *Applied Clinical Trials* 2007 Nov;16(11):42,44-5  

RS 2728  DiMasi JA  Grabowski HG.  Should the patent system for new medicines be abolished?  *Clinical Pharmacology & Therapeutics* 2007;82(5):488-90  
[http://www.nature.com/clpt/journal/v82/n5/full/6100393a.html](http://www.nature.com/clpt/journal/v82/n5/full/6100393a.html)

RS 2727  Cohen J.  CEA is not a price control (letter)  *Health Affairs* 2007;26(5):1505  
[http://content.healthaffairs.org/cgi/reprint/26/5/1505](http://content.healthaffairs.org/cgi/reprint/26/5/1505)

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2721 Kaitin KI, editor. Despite more cancer drugs in R&D, overall U.S. approval rate is 8%. *Tufts Center for the Study of Drug Development Impact Report* 2007 Sep/Oct;9(5)**


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2714  Getz KA. CRO shifts in the outsourcing market. *Applied Clinical Trials* 2007 May;16(5):35-6,8  


RS 2711  Getz KA. Industry trials poised to win back academia. *Applied Clinical Trials* 2007 Apr;16(4):40-2,4  

RS 2710  Getz KA  Sergeant E  Kremidas J. Mission possible: rebranding clinical research. *Applied Clinical Trials* 2007 Apr;16(4):35-6,8  


RS 2708  Getz K  Wenger J. High times for the CRO heavyweights. *Scrip supplements* 2007 Mar;5-6  


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2704  Getz KA. Drowning in the sea of regulatory compliance. *Applied Clinical Trials* 2007 Feb;16(2):32, 34
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=401621


RS 2626  Getz KA. Hitching a ride with the speed demons of drug development. *Applied Clinical Trials* 2006 Dec;15(12):22, 24
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=392454

http://www.thescientist.com/article/display/36886/

RS 2624  Cohen J, Cairns C, Paquette C, Faden L. Comparing patient access to pharmaceuticals in the UK and US. *Applied Health Economics and Health Policy* 2006;5(3):177-87


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=382875


RS 2619  Getz KA. Spotting the 'new' managed site networks. *Applied Clinical Trials* 2006 Sep;15(9):34,36  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=370345


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=334568

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


RS 2606  Getz KA.  Forgotten voices in the transparency debate: online trial registries alone will not succeed at rebuilding public confidence.  *Applied Clinical Trials* 2006 Apr;15(4):42, 44  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=316473


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website  http://csdd.tufts.edu
Kaitin KI, editor. CRO contribution to drug development is substantial and growing globally. *Tufts Center for the Study of Drug Development Impact Report* 2006 Jan/Feb;8(1)**


Getz KA. The imperative to support site adoption of EDC. *Applied Clinical Trials* 2006 Jan;15(1):38, 40


Getz KA. Have we pushed our PIs too far? *Applied Clinical Trials* 2005 Sep;14(9):34-6


Milne C-P  Kaitin KI. Down the critical path: who should lead? *Applied Clinical Trials* 2005 Aug;14(8):56


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**
RS 2513  Sugarman J  Getz K  Speckman JL  Byrne MM  Gerson J  Emanuel EJ  
Consortium to Evaluate Clinical Research Ethics. The cost of institutional review 
boards in academic medical centers.  New England Journal of Medicine 2005 Apr 
28;352(17):1825-7

RS 2512  DiMasi JA  Hansen RW  Grabowski HG.  Reply: setting the record straight on 
setting the record straight: response to the Light and Warburton rejoinder. 
Journal of Health Economics 2005 Sep;24(5):1049-53

RS 2511  DiMasi JA  Hansen RW  Grabowski HG.  Reply: extraordinary claims require 

RS 2510  Kaitin KI, editor.  Longer clinical times are extending time to market for new 
drugs in U.S.  Tufts Center for the Study of Drug Development Impact Report 
2005 Nov/Dec;7(6)**

RS 2509  Reichert JM  Rosensweig CJ  Faden LB  Dewitz MC.  Monoclonal antibody 
successes in the clinic.  Nature Biotechnology 2005 Sep;23(9):1073-8  
Also available at  
http://www.nature.com/nbt/journal/v23/n9/pdf/nbt0905-1073.pdf

RS 2508  Kaitin KI, editor.  Drug safety withdrawals in the U.S. not linked to speed of FDA 
approval.  Tufts Center for the Study of Drug Development Impact Report 2005 
Sep/Oct;7(5)**

RS 2507  Getz K  Kremidas J.  Educating the public: a critical, unmet need.  Applied 
Clinical Trials 2005 Mar;14(3):60-6 
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=149965

RS 2506  Kaitin KI, editor.  U.S. pediatric studies incentive led to new labeling for nearly 
100 drugs.  Tufts Center for the Study of Drug Development Impact Report 2005 
Jul/Aug;7(4)**

RS 2505  Kaitin KI, editor.  Numbers of active investigators in FDA-regulated clinical trials 
drop.  Tufts Center for the Study of Drug Development Impact Report 2005 
May/Jun;7(3)**

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


| RS 2423 | Milne C-P. Harbingers, or harvesters of change? *European Pharmaceutical Review Supplement (Outsourcing)* 2004 Winter:12-17

| RS 2422 | Reichert JM. Technology evaluation: Lumiliximab, Biogen Idec. *Current Opinion in Molecular Therapeutics* 2004;6(6):675-83


| RS 2419 | Cohen J. The emergence of a *de facto* fourth hurdle in the US. *Regulatory Affairs Journal -- Pharma* 2004 Dec;15(12):867-70

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


Kaitin KI, editor. Switching drugs from prescription to OTC status on rise in U.S. and EU. *Tufts Center for the Study of Drug Development Impact Report* 2003 Sep/Oct;5(5)**


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)
RS 2308  Kaitin KI, editor.  CROs provide gateway to worldwide clinical trial recruitment efforts.  Tufts Center for the Study of Drug Development Impact Report 2003 Jul/Aug;5(4)**


RS 2301  Kaitin KI, editor.  Increased pressure on drug industry is leading to greater focus on Japan.  Tufts Center for the Study of Drug Development Impact Report 2003 Jan/Feb;5(1)**


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu
RS 2220  Milne C-P  Lasagna L.  The cost and value of new medicines in an era of change.  
*PharmacoEconomics* 2002;20(Suppl 3).  *Includes:* DiMasi JA.  The value of improving the productivity of the drug development process: faster times and better decisions:1-10; Grabowski H  Vernon J  DiMasi JA.  Returns on research and development for 1990s new drug introductions:11-29; Lasagna L.  Concluding remarks


RS 2218  Kaitin KI, editor.  Approval times for new drugs fell by more than a year during PDUFA.  *Tufts Center for the Study of Drug Development Impact Report* 2002 Nov/Dec;4(6)**

RS 2217  Franco RJ  Kaitin KI.  Beyond the blockbuster: big pharma must rethink product development, striving for the speed and flexibility of mid-size players.  *Pharmaceutical Executive* 2002 Nov;22(11):74-80  
http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=36729


RS 2213  Kaitin KI, editor.  Approval times for priority-reviewed new drugs declined under PDUFA.  *Tufts Center for the Study of Drug Development Impact Report* 2002 Jul/Aug;4(4)**

http://www.nature.com/nbt/journal/v20/n7/pdf/nbt0702-659.pdf

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)
RS 2211  Cohen J  Chee J.  Pharmacy benefit managers’ role in facilitating Medicare beneficiary access to pharmaceutical care.  *Disease Management & Health Outcomes* 2002;10(4):221-7


RS 2204  Kaitin KI.  From the Editor-in-Chief: regulatory reform at the crossroads.  *Drug Information Journal* 2002;36(2):245-6  

RS 2203  Reichert JM  Therapeutic monoclonal antibodies: trends in development and approval in the US.  *Current Opinion in Molecular Therapeutics*  2002;4(2):110-8

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2123 Kaitin KI. El papel de la investigación básica. [editorial]. (Original title: The quest for cures -- the role of the research-based drug industry) La Vanguardia (Barcelona) 2001 18 Mar*

RS 2122 Kaitin KI, participant. The importance of innovation in pharmaceutical research. Pfizer Journal 2001;4(5)


RS 2119 DiMasi JA. Winners and losers in new drug innovation. Medical Marketing & Media 2001 Sep;36(9):99-110


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website  [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2102  Kaitin KI, editor.  FDA’s fast track program results in 62% approval rate after first 3 years.  *Tufts Center for the Study of Drug Development Impact Report* 2001 Jan/Feb;3(1)**


http://www.diahome.org/content/abstract/2000/dij1556.pdf

RS 2023  Cross-functional team focus on marketing is key to project success.  *Tufts Center for the Study of Drug Development Impact Report* 2000 Dec;2(9)  

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


RS 2018 Kaitin KI. Don’t turn back the clock on drug regulatory reform. *Tufts Center for the Study of Drug Development Impact Editorial* 2000 Sep;2(7)


http://www.acnp.org/g4/GN401000182/Default.htm

* This publication is not available from the Center. Please contact a library or the publisher.

** This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2008  Drug firms embrace pediatric study program during first 2 years of FDAMA.  *Tufts Center for the Study of Drug Development Impact Report* 2000 Apr;2(3)


*This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu**


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**

RS 9810  Lasagna L. Presentation of the Louis Lasagna Chair of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine. Journal of Clinical Pharmacology 1998;38:570-1, 575-6


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu

RS 9802  Lasagna L.  In pursuit of profitability and effectiveness in the global pharmaceutical industry: comments on Professor Walker’s four challenges.  Indiana Journal of Global Legal Studies 1997 Fall;5(1):85-92


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website  http://csdd.tufts.edu**


RS 9715  Kaitin KI.  FDA reform: setting the stage for efforts to reform the agency.  *Drug Information Journal* 1997;31(1):27-33

RS 9714  Lasagna L  DiMasi JA.  Let’s speed up the approval of new indications for old drugs.  *Medical Marketing & Media* 1996 Dec;31(12):88-9


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**
RS 9625 DiMasi JA. *Written testimony.* House Subcommittee on Human Resources and Intergovernmental Affairs, Committee on Government Reform and Oversight, U.S. House of Representatives. September 12, 1996


RS 9623 Kaitin KI. *Statement.* Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives. The Need for FDA Reform, February 27, 1996. 104th Congress 2d Session:81-7, 100-1


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website** [http://csdd.tufts.edu](http://csdd.tufts.edu)


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 9506  Shulman SR  Seibring M  Manocchia M. *Letter to Hon. Judd Gregg, U.S. Senate*. Hearing before the Subcommittee on Aging of the Committee on Labor and Human Resources, United States Senate, July 13, 1995 104th Congress 1st Session:47-8


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


PS 9596  Brown JS  DiMasi JA  Gosse ME  Manocchia M  Kaitin KI  Shulman SR.  Incentives for the development of drugs for AIDS and other life-threatening illnesses: points to consider.  For the Public/Private Issues and Development Subcommittees of the National Task Force on AIDS Drug Development meeting, April 25, 1995


RS 9594  Bloom BR.  The United States needs a national vaccine authority.  *Science* 1994 Sep 2;265(5177):1378-80


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 9496  Lasagna L.  *Statement of Louis Lasagna, M.D., Dean, Tufts Sackler School of Graduate Biomedical Sciences at the National Institutes of Health CRADA forum, July 21, 1994.*  Washington DC: New England Biomedical Research Coalition, 1994


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 9485  Inman WHW. Drug Safety Research Unit, University of Southampton. PEM News 1993 Nov;(8)

RS 9484  Smith ND. Quality of life studies from the perspective of an FDA reviewing statistician. Drug Information Journal 1993;27(3):617-23


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


RS 9274  Shulman SR  Raiford DS.  Promotional elements in educational programs: FDA attempts to wipe the slate clean.  *P&T* 1992;17:661-73*


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 9266 Scoville B. Shifting the burden: restructuring the drug review process. *Journal of Clinical Pharmacology and Therapeutics* 1991 Mar;49(3):229-33


* This publication is not available from the Center. Please contact a library or the publisher.
**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)
RS 9162  Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News* 1991 Aug;(7)


RS 9158  DiMasi JA Lasagna L. Development of supplemental indications for already-approved drugs by the United States pharmaceutical industry. *Journal of Clinical Research and Pharmacoepidemiology* 1991;5:19-33


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**
RS 9054  Shulman SR.  La legislazione sulla responsibilità di produzione.  *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:27-8

RS 9053  Lasagna L.  Le attività del Centro per lo Studio dello Sviluppo dei Farmaci.  *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:26

RS 9052  Inman WHW.  Drug Safety Research Unit, University of Southhampton, *PEM News* 1988 Sep(5)


RS 9048  Shulman SR Raiford DS.  FDA regulations provide broader access to unapproved drugs.  *Journal of Clinical Pharmacology* 1990;30:585-7


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 8941  Kaitin KI. Reply to “understanding comparisons of drug introductions between the United States and the United Kingdom”. *Clinical Pharmacology & Therapeutics* 1989 Aug;46(2);146-8


RS 8934  Grabowski HG. Medicaid patients' access to new drugs. *Health Affairs* 1989;7:102-14


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 8930  Inman WHW.  Drug Safety Research Unit, University of Southampton.  *PEM News* 1988 Sep;(5)


RS 8830  Shulman SR.  Drug refusal policy must include legal definition of competence.  *Hospital Formulary* 1988 Jan;23:79

RS 8829  DiMasi JA.  The notion of "acceptable risk": comment.  *Journal of Clinical Epidemiology* 1988;41(9):939-41


RS 8824  Wittes RE.  Antineoplastic agents and FDA regulations: square pegs for round holes?  *Cancer Treatment Reports* 1987;71:795-806

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**

*This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 8710 Inman WHW. Drug Safety Research Unit, University of Southampton, *PEM News* 1987 Mar;(4)


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**

RS 8705  Kaitin KI.  Impact of generic drugs on the pharmaceutical marketplace.  *Private Practice* 1986 Sep;18:18-20  (Originally appeared as "Generic firms shun research, share rewards.")


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website** [http://csdd.tufts.edu]


RS 8600  Berry CL. Unprovable verities. *Human Toxicology* 1985;5(3):159-60

RS 8699  Weintraub M, Northington F. Drugs that wouldn't die. *Journal of the American Medical Association* 1986 May 2;255(17):2327-8


RS 8696  Inman WHW. Drug Surveillance Research Unit, University of Southampton. *PEM News* 1985 Dec;(3)


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 8591  Mattison N.  Sources of change affecting the U.S. pharmaceutical industry in the 1980s.  *Pharmaceutical Medicine* 1985;1:13-6*


RS 8585  Spivey RN  Lasagna L  Trimble AG.  New drug applications: how long to gain approval?  *Clinical Pharmacology and Therapeutics* 1985 Apr;37(4):361-6


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 8477  Inman WHW.  Drug Surveillance Research Unit, University of Southampton, PEM News 1984 Aug;(2)


RS 8474-B  Weintraub M.  P&T committees and drug regulation in Norway: lessons to be learned.  Hospital Formulary 1984;19:347

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


RS 8468  Hutt PB. The importance of patent term restoration to pharmaceutical innovation: will extending patent life increase drug innovation? A search for answers. *Health Affairs* 1982;1(2):5-24


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)

RS 8367  Superior Court of New Jersey, Appellate Division. Carol Ann Feldman, an infant, by her parent and guardian ad litem Harold Feldman, Plaintiffs - Appellants vs. Lederle Laboratories, a corporation, and American Cyanamid Co., a corporation, Defendants - Respondents. Nov 1983

RS 8366  Inman WHW. Drug Surveillance Research Unit, University of Southampton. PEM News 1983 Aug;(1)

RS 8365  Covington TR. Toward a rational approach to the issue of prescribing authority for pharmacists. Drug Intelligence and Clinical Pharmacy 1983 Sep;17(9):660-6


RS 8363  Young JH. Public policy and drug innovation. The American Institute of the History of Pharmacy 1982;24:1-56

RS 8362  Paton WD. Animal experimentation and medical research: a study in evolution. Conquest 1979 Feb;169:1-14

RS 8361  Hutt PB. Investigations and reports respecting FDA regulation of new drugs, Part I) and Part II. Clinical Pharmacology and Therapeutics 1983;33(4):537-48; 33(5):674-87


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu
RS 8359-C Diggle GE Griffin JP. Licensing times in granting marketing authorizations for medicines--a comparison between the U.K. and U.S.A. Pharmacy International 1982;3(7):230-6


RS 8262 Wardell WM. Is pharmaceutical innovation declining? Pharmaceutical Technology 1982 Sep


RS 8260 Wardell WM Mattison N. The assessment of medical technologies using risk-benefit, cost-benefit, and cost-effectiveness analysis. In: WMA Follow-up Committee on Development and Allocation of Medical Care Resources. Tokyo: Japan Medical Association, 1982;84-98*

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


RS 8252 Shubin S. The MAC program and advisors to the government. Hospital Formulary 1981 Aug;16(8):869-79


RS 8250 Wardell WM. A statement on pharmaceutical patent life and innovation. Submitted to the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives. Feb 4, 1982

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


RS 8153 Wardell WM Velo GP, editors. Drug development, regulatory assessment, and postmarketing surveillance. NATO Advanced Institutes Series, 39 (Series A: Life Sciences) New York: Plenum, 1981*


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 8141-B  Lasagna L.  Dear hearts.  The Sciences 1980 Oct;29:29

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu

RS 8059  Hansen RW. *Effects of incremental costs on pharmaceutical innovation*. (Working Paper Series No. GPB-81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

RS 8058  Hansen RW. *The cost of regulation in the pharmaceutical industry: economic implications of three recent studies*. (Working Paper Series No. PS 81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

RS 8057  Wardell WM. Therapeutic drugs as an example of the regulation of health care: efficient and inefficient ways of utilizing resources. In: *Proceeding of the World Medical Association Follow-Up Committee Meeting on Development and Allocation of Medical Care Resources*. Tokyo: Japan Medical Association, 1980:139-50*

RS 8056  Wardell WM. Drug therapy (a response to questions on specific aspects of drug regulation). *Private Practice* 1980 Oct:24-31*


RS 8051  Lasagna L. Pharmacology's labs have moved faster than the regulators. *Medical Tribune* 1980 May 7;21:17

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 8046  Hansen RW. Pharmaceutical development costs by therapeutic categories. (Working Paper Series No. GPB-80-6) Rochester NY: Graduate School of Management, University of Rochester, Mar 1980*


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


PS 8032  Merrill RA. *Problems involving federal conflict of interest restrictions on members of FDA advisory committees and agency officials*. Rochester NY: Center for the Study of Drug Development, Apr 1980


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**

RS 7939 Lasagna L. Toxicological barriers to providing better drugs. *Archives of Toxicology* 1979;43(1):27-33

RS 7938 Lasagna L. Prescription drugs: the investment with the biggest dividends. *Private Practice* 1979 May;11(5):42-3


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**
| RS 7930 | Lasagna L.  The uncertain future of drug development.  *Drug Intelligence and Clinical Pharmacy* 1979 Apr;13(4):192-4 |
| RS 7926-A | Lasagna L.  The diseases and drug needs of the Third World.  *Journal of Chronic Diseases* 1979;32(6):413-4 |

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**

Lasagna L. Generic substitution: trick or treat? *Journal of the American Medical Association* 1978 May;239(18):1888


Wardell WM. A close inspection of the 'calm look': rhetorical amblyopia and selective amnesia at the FDA. *Journal of the American Medical Association* 1978;239(19):2004-11


*This publication is not available from the Center. Please contact a library or the publisher.*

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


PS 7816 Landau RL. What you should know about estrogens, or the perils of Pauline. Rochester NY: Center for the Study of Drug Development, Jun 1978


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu